EP Patent

EP3920938A1 — Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Assigned to Eirgen Pharma Ltd · Expires 2021-12-15 · 4y expired

What this patent protects

Methods and compositions for controlling hyperparathyroidism are disclosed.

USPTO Abstract

Methods and compositions for controlling hyperparathyroidism are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3920938A1
Jurisdiction
EP
Classification
—
Expires
2021-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Eirgen Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.